Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

closed

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.